Skip to main content
PharmaTher Holdings Ltd. logo

PharmaTher Holdings Ltd. — Investor Relations & Filings

Ticker · PHRM ISIN · CA71716H1082 LEI · 529900PIPSZ1ZSWF3A21 CSE Manufacturing
Open in API
Filings indexed 279 across all filing types
Latest filing 2023-07-18 Capital/Financing Update
Country CA Canada
Listing CSE PHRM

About PharmaTher Holdings Ltd.

https://www.pharmather.com/

PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing positive research results for a pharmaceutical product (PharmaPatch™) and a strategic investment into another company (Sairiyo Therapeutics). It contains no financial statements, no detailed financial performance data, no regulatory filings, no voting results, no management or board changes, no earnings data, and no legal proceedings. It is a corporate announcement about research progress and investment activity. This fits best under Capital/Financing Update (CAP) because it includes information about a strategic investment and ownership percentages, which are financing-related activities. The document length is 9348 characters, which is substantial but the content is clearly an announcement rather than a full financial report or regulatory filing. Therefore, the classification is CAP with high confidence.
2023-07-18 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the filing of an Abbreviated New Drug Application (ANDA) with the FDA for a pharmaceutical product, KETARX™. It discusses expected approval timelines and commercial launch plans. There are no financial statements, detailed financial performance data, or regulatory certifications. The content is an update on a capital/financing-related activity (filing for drug approval and anticipated commercialization), which aligns with Capital/Financing Update filings. The document is not a report itself but an announcement of a significant corporate development related to financing and regulatory approval. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-06-27 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a collaboration agreement between PharmaTher and Vitruvias for the commercialization of a pharmaceutical product (KETARX™) in the U.S. It discusses expected FDA approval timelines, commercial launch plans, and partnership roles. There are no financial statements, regulatory filings, voting results, or management changes detailed. The content focuses on a business collaboration and commercialization update rather than financial results or regulatory filings. This type of announcement fits best under Capital/Financing Update (CAP) as it relates to a strategic commercial partnership and future product launch plans, which are typical of capital or financing-related updates. The document length is 7440 characters, sufficient for a detailed announcement but not a full financial report or regulatory filing. Therefore, the classification is CAP with high confidence.
2023-06-20 English
News release - English.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Krishna Kumar as President and Chief Operating Officer of Akumin Inc. It focuses on management changes and provides background information on the new appointee. There is no financial data, no mention of a report or filing, and no regulatory or voting information. The content clearly fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2023-06-12 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the submission of a Fast Track Application to the FDA for a drug (KETARX™) for the treatment of Parkinson's disease. It discusses clinical trial phases, drug development, and regulatory interactions but does not contain financial statements, earnings data, or detailed financial analysis. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing or certification document. The content is primarily an update on a capital/financing or development activity related to the company's drug pipeline and regulatory progress. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2023-05-02 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO, certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended February 28, 2023. It explicitly states it is a certification related to interim filings, not the filings themselves. The document is short (3058 characters) and primarily an officer certification letter. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS), not as the interim report itself (IR).
2023-04-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.